Key Points - Capricor Therapeutics, Inc. reports Q2 earnings amidst ongoing securities fraud class action lawsuit - Notice of September 28, 2026, application deadline for class action lawsuit issued - Shareholders who lost money have the opportunity to lead securities fraud lawsuit against Capricor - Lawsuit alleges material misstatements and/or omissions regarding lead product candidates...
Following are the Top 5 companies based on their one-day percentage change within the 'Future Communications...
Lyra Therapeutics, Inc. (LYRA) confirmed earnings release on August 21, 2026, for the quarter ending June...
Yiren Digital Ltd. (YRD) confirmed earnings release on August 21, 2026, Before the market for the...
Kandi Technologies Group, Inc. (KNDI) confirmed earnings release on August 21, 2026, Before the market for...
Danielle Brill from Truist Financial issued a price target of $20.00 for SLDB on 2026-08-21 11:27:42.The adjusted price target was set to $20.00.At the time of the announcement, SLDB was...
from Credit Suisse issued a price target of $3.50 for CCIF on 2026-08-21 10:37:04.The adjusted price target was set to $3.50.At the time of the announcement, CCIF was trading at...
from Goldman Sachs issued a price target of $575.00 for PRAX on 2026-08-21 10:23:06.The adjusted price target was set to $575.00.At the time of the announcement, PRAX was trading at...
Harsh Kumar from BMO Capital issued a price target of $35.00 for QBTS on 2026-08-20 20:33:59.The adjusted price target was set to $35.00.At the time of the announcement, QBTS was...
from Industrial Alliance Securities issued a price target of $3.25 for CCIF on 2026-08-20 18:51:10.The adjusted price target was set to $3.25.At the time of the announcement, CCIF was trading...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
